

Avantor recognized for advancing biopharmaceutical manufacturing and enabling efficiencies in upstream processes

June 25, 2021 | News

Avantor Named Best Company in Bioprocessing Excellence for Single-use Solutions and Best Bioprocessing Supplier for Upstream Processing at Biologics Manufacturing Korea 2021



Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies and applied materials industries, was named best company in bioprocessing excellence for single-use solutions and best bioprocessing supplier for upstream processing at Biologics Manufacturing Korea (BMK) 2021.

This is the second consecutive year Avantor has been selected as the best company in the single-use category at BMK. As the development and supply of biopharmaceuticals, including COVID-19 vaccines and therapeutics, become more important than ever, Avantor has been actively supporting the discovery to delivery of biopharmaceutical therapies to both domestic and foreign pharmaceutical companies. A key piece of this contribution is supplying differentiated upstream solutions such as high-purity materials.

Avantor also has been recognized for its ongoing efforts to develop [single-use solutions](#), which are emerging as the preferred option to improving biopharmaceutical manufacturing processes. Avantor is responding to rapidly increasing needs for treatments and therapies by providing customized solutions to biopharma companies. Avantor closely analyzes manufacturing processes to support customers with increased yield and reduced resources when developing new therapeutics.

SK Lee, Sales Director of Avantor Korea & Japan, said, "We are extremely proud to be recognized by BMK for our leadership in bioprocessing development by providing solutions to biopharmaceutical manufacturers. Working closely with our customers, we play a critical role in enabling breakthroughs in life-changing biologics."

Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, "Avantor's continued investment in single-use solutions, including our [recent acquisition of RIM Bio](#), with manufacturing capabilities in China, go

a long way to demonstrate our commitment to delivering bioprocessing excellence. Our process development and optimization capabilities carried out by our dedicated expert researchers at our Korea Innovation Center is helping customers deliver on cost and time efficiencies."